SION
Sionna Therapeutics, Inc.Healthcare·Biotechnology
$42.82
$1.9B market cap
Revenue
$0.0M
Free Cash Flow
$-38.7M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
2-Year Price History
$41.13+64.5%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -29.5 | -29.6 | -26.8 | -21.8 | -21.8 | -0.0 | 216.2 | 8.4 | 44.9 | -134.7% | -- | -- |
| Act | 2025-Q4 | 0.0 | -17.9 | -23.6 | -20.4 | -16.6 | -16.8 | -0.2 | 235.9 | 8.7 | 40.0 | -87.2% | -- | -- |
Valuation & Metrics
Market Stats
Price$42.82
Market Cap$1.9B
Enterprise Value$1.7B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-2.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-47.2M
Free Cash Flow$-38.7M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-110.9%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares4.2M
Days to Cover9.3
Change (vs Prior)+11.3%
Need at least 2 settlement dates for chart
Employees
Headcount41
Revenue / Employee$0
Gross Profit / Employee$-7,463
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
88.6%(+65.9% YoY)
111 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
8.2%(+7.7% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
0.0%(+0.0% YoY)
2 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $397M | $10.46 | +$0 | −$21.7M | -4.7% | $9.44B |
| TPG GP A, LLC | $260M | $10.52 | −$10.0M | −$7.6M | -2.9% | $3.32B |
| ORBIMED ADVISORS LLC | $142M | $10.46 | −$1.2M | −$7.0M | -8.2% | $4.38B |
| VIKING GLOBAL INVESTORS LP | $128M | $10.98 | +$0 | +$9.7M | +1.0% | $35.75B |
| Atlas Venture Life Science Advisors, LLC | $120M | $10.46 | +$0 | −$28.0M | +1.2% | $790M |
| Enavate Sciences GP, LLC | $99.3M | $10.46 | +$0 | +$0 | +7.7% | $352M |
| JENNISON ASSOCIATES LLC | $58.2M | $22.14 | +$13.5M | +$23.7M | +2.7% | $145.31B |
| JPMORGAN CHASE & CO | $53.7M | $13.42 | +$9.3M | −$25.8M | -0.2% | $1.47T |
| BlackRock, Inc.Passive | $52.0M | $26.51 | +$171K | +$44.0M | -0.2% | $5.69T |
| CITADEL ADVISORS LLC | $46.8M | $34.21 | +$3.2M | +$33.7M | -0.4% | $138.22B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $41.3M | $40.09 | +$41.3M | +$41.3M | — | $4.04T |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $38.9M | $12.05 | +$0 | +$9.0M | -0.9% | $7.18B |
| PRICE T ROWE ASSOCIATES INC /MD/ | $30.3M | $15.45 | −$3.0M | −$9.6M | -0.2% | $864.93B |
| STATE STREET CORPPassive | $30.3M | $35.21 | +$2.5M | +$29.7M | -0.2% | $2.89T |
| PERCEPTIVE ADVISORS LLC | $26.4M | $10.46 | −$20.9M | −$23.8M | -1.4% | $5.05B |
| EVENTIDE ASSET MANAGEMENT, LLC | $25.9M | $41.13 | +$260K | +$25.9M | -1.6% | $5.96B |
| Aberdeen Group plc | $22.6M | $11.94 | −$11.1M | −$7.3M | -0.6% | $61.88B |
| BAKER BROS. ADVISORS LP | $16.0M | $10.46 | +$0 | +$0 | -0.5% | $16.13B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $15.6M | $20.25 | +$394K | +$10.2M | +2.3% | $1.61T |
| Siren, L.L.C. | $12.0M | $10.46 | +$0 | −$1.0M | +6.1% | $3.61B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-1.33%
avg per quarter
Holders (ex-self)
-1.68%
excl. this stock
Buyers (this Q)
+0.22%
64 buyers · $0.15B in
Sellers (this Q)
-1.71%
32 sellers · $0.07B out
alpha coverage: 97% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-2.4%
how holders react when this stock falls
On quiet Qs
-1.4%
−10% to +10% baseline
On rallies (+10%+)
-11.4%
how they react when this stock rises
Holders' portfolio flow this Q
+3.0%
inflows — adds are organic
Sellers' portfolio flow this Q
+10.3%
Sellers grew AUM elsewhere — opinionated cut of this stock.
Biggest decreases this quarter
PERCEPTIVE ADVISORS LLC−$20.9Mα-1.4Aberdeen Group plc−$11.1Mα-0.6TPG GP A, LLC−$10.0Mα-2.9PRICE T ROWE ASSOCIATES INC /MD/−$3.0Mα-0.2ORBIMED ADVISORS LLC−$1.2Mα-8.2SG Americas Securities, LLCexited−$440KAMERICAN CENTURY COMPANIES INCexited−$254KDARK FOREST CAPITAL MANAGEMENT LPexited−$246KD. E. Shaw & Co., Inc.exited−$236KProShare Advisors LLCexited−$202K
New buyers this quarter
Top-5 holders · 57.7%
RA CAPITAL MANAGEMENT, L.P.--
TPG GP A, LLC--
ORBIMED ADVISORS LLC--
VIKING GLOBAL INVESTORS LP--
Atlas Venture Life Science Advisors, LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
RA CAPITAL MANAGEMENT, L.P.9.9MTPG GP A, LLC6.5MORBIMED ADVISORS LLC3.5MVIKING GLOBAL INVESTORS LP3.2MAtlas Venture Life Science Advisors, LLC3.0MEnavate Sciences GP, LLC2.5MJPMORGAN CHASE & CO1.5MJENNISON ASSOCIATES LLC1.5MPERCEPTIVE ADVISORS LLC658KCITADEL ADVISORS LLC1.2M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (2 analysts)$52.502260.0%
Last Year (7 analysts)$43.86240.0%
Current Price$42.82
Analyst Ratings
4
1
1
Buy: 4Hold: 1Sell: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$124.47M
65 txns · 6 insiders · 3,080,442 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$950K
1 txn · 1 insider · 60,000 sh
Sells ($, 12mo)
$31.46M
8 txns · 2 insiders · 790,277 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | SELL | ORBIMED ADVISORS LLC | director | 184,639 | $46.22 | $8.53M | $123.49M |
| 2026-05-11 | SELL | Thompson Peter A. | director | 184,639 | $46.22 | $8.53M | $123.49M |
| 2026-05-08 | SELL | ORBIMED ADVISORS LLC | director | 59,767 | $44.58 | $2.66M | $127.34M |
| 2026-05-08 | SELL | Thompson Peter A. | director | 59,767 | $44.58 | $2.66M | $127.34M |
| 2026-05-07 | SELL | ORBIMED ADVISORS LLC | director | 48,546 | $44.61 | $2.17M | $130.09M |
| 2026-05-07 | SELL | Thompson Peter A. | director | 48,546 | $44.61 | $2.17M | $130.09M |
| 2026-04-18 | SELL | ORBIMED ADVISORS LLC | director | 2,948 | $44.52 | $131K | $131.99M |
| 2026-04-18 | SELL | Thompson Peter A. | director | 2,948 | $44.52 | $131K | $131.99M |
| 2026-04-17 | SELL | Thompson Peter A. | director | 52,397 | $44.68 | $2.34M | $132.60M |
| 2026-04-17 | SELL | ORBIMED ADVISORS LLC | director | 52,397 | $44.68 | $2.34M | $132.60M |
| 2026-04-16 | SELL | ORBIMED ADVISORS LLC | director | 226,906 | $45.34 | $10.29M | $136.93M |
| 2026-04-16 | SELL | Thompson Peter A. | director | 226,906 | $45.34 | $10.29M | $136.93M |
| 2026-04-15 | SELL | ORBIMED ADVISORS LLC | director | 235,863 | $44.64 | $10.53M | $144.95M |
| 2026-04-15 | SELL | Thompson Peter A. | director | 235,863 | $44.64 | $10.53M | $144.95M |
| 2026-04-14 | SELL | ORBIMED ADVISORS LLC | director | 47,814 | $44.51 | $2.13M | $155.02M |
| 2026-04-14 | SELL | Thompson Peter A. | director | 47,814 | $44.51 | $2.13M | $155.02M |
| 2026-03-05 | SELL | Fitzpatrick Jennifer | officer: Chief Legal Officer | 10,250 | $33.86 | $347K | $0 |
| 2026-02-03 | SELL | Thompson Peter A. | director | 29,063 | $44.58 | $1.30M | $157.40M |
| 2026-02-03 | SELL | ORBIMED ADVISORS LLC | director | 29,063 | $44.58 | $1.30M | $157.40M |
| 2026-02-02 | SELL | ORBIMED ADVISORS LLC | director | 1,890 | $44.57 | $84K | $158.66M |
Order Flow (FINRA, ~3w lag)
10.8%retail+6.0pp
45.7%dark-2.5pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Sionna Therapeutics: Milestone Avalanche and Perpetual Dilution Engines
Overall Risk
4/10
Fraud
2/10
Dilution
8/10
Insolvency
3/10
Earnings Overstated
2/10
Hidden Liabilities
7/10
Legal
2/10
Audit Warnings
2/10
Hidden Upside
5/10
Contextually Acceptable
8/10